Details of the Drug

General Information of Drug (ID: DMZC90K)

Drug Name

Vitamin E

Synonyms

Covi-ox; VITAMIN E; E-Vimin; Syntopherol; Profecundin; Evitaminum; Viprimol; Vascuals; Etamican; Viteolin; Tokopharm; Vitayonon; Epsilan; Emipherol; Denamone; Almefrol; Verrol; Ilitia; Etavit; 77171-98-3; Evion; Esorb; alpha-Tokoferol; alpha Tocopherol; Vitaplex E; Vitamin E alpha; Eprolin S; Viterra E; E Prolin; Spavit E; Vita E; Endo E; Med-E; Lan-E; Antisterility vitamin; alpha-Tocopherol acid; Tenox GT 1; (R)-2,5,7,8-tetramethyl-2-((4S,8S)-4,8,12-trimethyltridecyl)chroman-6-ol; Rhenogran Ronotec 50; Vi-E; Covitol F 1000; E 307 (tocopherol)

Indication

Disease Entry	ICD 11	Status	REF
Atherosclerosis	BD40	Approved	[1]
Cardiovascular disease	BA00-BE2Z	Approved	[2]
Carotid artery disease	8B10	Approved	[1]
Coagulation defect	3B10.0	Approved	[1]
Hypercholesterolaemia	5C80.0	Approved	[1]
Intracranial arteriosclerosis	N.A.	Approved	[1]
Cardiac disease	BA00-BE2Z	Investigative	[1]


⏷ Show the Full List of Indication(s)

Affected Organisms

Humans and other mammals

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 2

Molecular Weight (mw)

430.7

Logarithm of the Partition Coefficient (xlogp)

10.7

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

Chemical Identifiers

Formula: C29H50O2
IUPAC Name: (2R)-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-ol
Canonical SMILES: CC1=C(C2=C(CC[C@@](O2)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)C(=C1O)C)C
InChI: InChI=1S/C29H50O2/c1-20(2)12-9-13-21(3)14-10-15-22(4)16-11-18-29(8)19-17-26-25(7)27(30)23(5)24(6)28(26)31-29/h20-22,30H,9-19H2,1-8H3/t21-,22-,29-/m1/s1
InChIKey: GVJHHUAWPYXKBD-IEOSBIPESA-N

Cross-matching ID

PubChem CID: 14985
ChEBI ID: CHEMBL47
CAS Number: 59-02-9
UNII: N9PR3490H9
DrugBank ID: DB00163
TTD ID: D02TQO
INTEDE ID: DR1701

Drug-Molecule Activity Atlas (DMA)^NEW

Click to Jump to the Detailed DMA Information of This Drug

Drug Pharmacogenomic Perturbation (DPP)^NEW

Click to Jump to the Detailed DPP Information of This Drug

Drug ADMET Endpoint Profile (DAE)^NEW

Click to Jump to the Detailed DAE Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)_{Main DME}	DE4LYSA	CP3A4_HUMAN	Substrate	[3]

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Vitamin E (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Cilostazol	DMZMSCT	Moderate	Increased risk of bleeding by the combination of Vitamin E and Cilostazol.	Arterial occlusive disease [BD40]	[4]
Anisindione	DM2C48U	Moderate	Increased risk of bleeding by the combination of Vitamin E and Anisindione.	Coagulation defect [3B10]	[4]
Ardeparin	DMYRX8B	Moderate	Increased risk of bleeding by the combination of Vitamin E and Ardeparin.	Coronary thrombosis [BA43]	[4]
Danaparoid	DM6CLBN	Moderate	Increased risk of bleeding by the combination of Vitamin E and Danaparoid.	Deep vein thrombosis [BD71]	[4]
Rivaroxaban	DMQMBZ1	Moderate	Increased risk of bleeding by the combination of Vitamin E and Rivaroxaban.	Deep vein thrombosis [BD71]	[4]
Sulfinpyrazone	DMEV954	Moderate	Increased risk of bleeding by the combination of Vitamin E and Sulfinpyrazone.	Gout [FA25]	[4]
Tipranavir	DM8HJX6	Major	Increased risk of bleeding by the combination of Vitamin E and Tipranavir.	Human immunodeficiency virus disease [1C60-1C62]	[5]
Dipyridamole	DMXY30O	Moderate	Increased risk of bleeding by the combination of Vitamin E and Dipyridamole.	Hypertension [BA00-BA04]	[4]
Ticlopidine	DMO946V	Moderate	Increased risk of bleeding by the combination of Vitamin E and Ticlopidine.	Ischaemic/haemorrhagic stroke [8B20]	[4]
Ibrutinib	DMHZCPO	Major	Increased risk of bleeding by the combination of Vitamin E and Ibrutinib.	Mature B-cell lymphoma [2A85]	[6]
Prasugrel	DM7MT6E	Moderate	Increased risk of bleeding by the combination of Vitamin E and Prasugrel.	Myocardial infarction [BA41-BA43]	[4]
Vorapaxar	DMA16BR	Moderate	Increased risk of bleeding by the combination of Vitamin E and Vorapaxar.	Myocardial infarction [BA41-BA43]	[4]
Tirofiban	DMQG17S	Moderate	Increased risk of bleeding by the combination of Vitamin E and Tirofiban.	Myocardial infarction [BA41-BA43]	[4]
Orlistat	DMRJSP8	Minor	Decreased absorption of Vitamin E caused by Orlistat.	Obesity [5B80-5B81]	[7]
Aspirin	DM672AH	Moderate	Increased risk of bleeding by the combination of Vitamin E and Aspirin.	Pain [MG30-MG3Z]	[8]
Treprostinil	DMTIQF3	Moderate	Increased risk of bleeding by the combination of Vitamin E and Treprostinil.	Pulmonary hypertension [BB01]	[4]
Epoprostenol	DMUTYR2	Moderate	Increased risk of bleeding by the combination of Vitamin E and Epoprostenol.	Pulmonary hypertension [BB01]	[4]
Iloprost	DMVPZBE	Moderate	Increased risk of bleeding by the combination of Vitamin E and Iloprost.	Pulmonary hypertension [BB01]	[4]
Warfarin	DMJYCVW	Moderate	Increased risk of bleeding by the combination of Vitamin E and Warfarin.	Supraventricular tachyarrhythmia [BC81]	[4]
Caplacizumab	DMPUKA7	Moderate	Increased risk of bleeding by the combination of Vitamin E and Caplacizumab.	Thrombocytopenia [3B64]	[4]
Apixaban	DM89JLN	Moderate	Increased risk of bleeding by the combination of Vitamin E and Apixaban.	Thrombosis [DB61-GB90]	[4]
Cangrelor	DM8JRH0	Moderate	Increased risk of bleeding by the combination of Vitamin E and Cangrelor.	Thrombosis [DB61-GB90]	[4]
Brilinta	DMBR01X	Moderate	Increased risk of bleeding by the combination of Vitamin E and Brilinta.	Thrombosis [DB61-GB90]	[4]
Argatroban	DMFI46A	Moderate	Increased risk of bleeding by the combination of Vitamin E and Argatroban.	Thrombosis [DB61-GB90]	[4]
Dicumarol	DMFQCB1	Moderate	Increased risk of bleeding by the combination of Vitamin E and Dicumarol.	Thrombosis [DB61-GB90]	[8]
Clopidogrel	DMOL54H	Moderate	Increased risk of bleeding by the combination of Vitamin E and Clopidogrel.	Thrombosis [DB61-GB90]	[4]
Betrixaban	DM2C4RF	Moderate	Increased risk of bleeding by the combination of Vitamin E and Betrixaban.	Venous thromboembolism [BD72]	[4]


⏷ Show the Full List of 27 DDI Information of This Drug

References

1	Riboflavin FDA Label
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3	Adverse effects of vitamin E by induction of drug metabolism. Genes Nutr. 2007 Dec;2(3):249-56.
4	Booth SL, Golly I, Sacheck JM, Roubenoff R, Dallal GE, et al "Effect of vitamin E supplementation on vitamin K status in adults with normal coagulation status." Am J Clin Nutr 80 (2004): 143-8. [PMID: 15213041]
5	Product Information. Aptivus (tipranavir). Boehringer-Ingelheim, Ridgefield, CT.
6	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
7	Product Information. Xenical (orlistat). Roche Laboratories, Nutley, NJ.
8	Gonzalez-Correa JA, Arrebola MM, Guerrero A, et al. "Influence of vitamin E on the antiplatelet effect of acetylsalicylic acid in human blood." Platelets 16(3-4) (2005): 171-9. [PMID: 16011961]